These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 21235427)
1. Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma. Rebecca VW; Smalley KS Expert Opin Investig Drugs; 2011 Feb; 20(2):137-40. PubMed ID: 21235427 [No Abstract] [Full Text] [Related]
2. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Lim SY; Menzies AM; Rizos H Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695 [TBL] [Abstract][Full Text] [Related]
4. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma. Cohen JV; Sullivan RJ Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297 [TBL] [Abstract][Full Text] [Related]
5. Targeting BRAF in melanoma: biological and clinical challenges. Mandalà M; Voit C Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641 [TBL] [Abstract][Full Text] [Related]
6. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma. Long G Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501 [No Abstract] [Full Text] [Related]
7. BRAF in melanoma: current strategies and future directions. Salama AK; Flaherty KT Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823 [TBL] [Abstract][Full Text] [Related]
8. Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. Tangella LP; Clark ME; Gray ES Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129736. PubMed ID: 32956754 [TBL] [Abstract][Full Text] [Related]
9. [New treatment options for metastatic melanoma]. Tietze JK; Berking C Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194 [No Abstract] [Full Text] [Related]
10. Tumor adaptation and resistance to RAF inhibitors. Lito P; Rosen N; Solit DB Nat Med; 2013 Nov; 19(11):1401-9. PubMed ID: 24202393 [TBL] [Abstract][Full Text] [Related]
11. BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospects. Rahman MA; Salajegheh A; Smith RA; Lam AK Curr Cancer Drug Targets; 2014; 14(2):128-43. PubMed ID: 24446739 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter. Bernhardt M; Orouji E; Larribere L; Gebhardt C; Utikal J Clin Cancer Res; 2014 May; 20(9):2498-9. PubMed ID: 24789037 [No Abstract] [Full Text] [Related]
13. On or off target: mutations, models, and predictions. Garraway LA; Hahn WC Sci Transl Med; 2010 Jun; 2(35):35ps28. PubMed ID: 20538617 [TBL] [Abstract][Full Text] [Related]
15. Targeting melanoma: unusual epigenetics reveals the dynamic rewiring of metastatic cells. Vizoso M; Esteller M Epigenomics; 2015 Oct; 7(7):1079-81. PubMed ID: 26541242 [No Abstract] [Full Text] [Related]
16. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents. Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019 [TBL] [Abstract][Full Text] [Related]
17. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge]. Capovilla M Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719 [TBL] [Abstract][Full Text] [Related]
18. Deja Vu: EGF receptors drive resistance to BRAF inhibitors. Girotti MR; Marais R Cancer Discov; 2013 May; 3(5):487-90. PubMed ID: 23658295 [TBL] [Abstract][Full Text] [Related]